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Abstract
Background: To estimate the occurrence and type of adverse effects after application of an extra-articular (soft
tissue) corticosteroid injection.
Methods: A systematic review of the literature was made based on a PubMed and Embase search covering the
period 1956 to January 2010. Case reports were included, as were prospective and retrospective studies that
reported adverse events of corticosteroid injection. All clinical trials which used extra-articular corticosteroid
injections were examined. We divided the reported adverse events into major (defined as those needing
intervention or not disappearing) and minor ones (transient, not requiring intervention).
Results: The search yielded 87 relevant studies:44 case reports, 37 prospective studies and 6 retrospective studies.
The major adverse events included osteomyelitis and protothecosis; one fatal necrotizing fasciitis; cellulitis and
ecchymosis; tendon ruptures; atrophy of the plantar fat was described after injecting a neuroma; and local skin
effects appeared as atrophy, hypopigmentation or as skin defect. The minor adverse events effects ranged from
skin rash to flushing and disturbed menstrual pattern. Increased pain or steroid flare after injection was reported in
19 studies. After extra-articular injection, the incidence of major adverse events ranged from 0-5.8% and that of
minor adverse events from 0-81%. It was not feasible to pool the risk for adverse effects due to heterogeneity of
study populations and difference in interventions and variance in reporting.
Conclusion: In this literature review it was difficult to accurately quantify the incidence of adverse effects after
extra-articular corticosteroid injection. The reported adverse events were relatively mild, although one fatal reaction
was reported.
Background
In 1954 the first report on the effects of corticosteroids on
healthy tissues appeared [1]. Local extra-articulair injec-
tions of glucocorticoid agents are currently used for rheu-
matic disorders including a wide spectrum of localised
lesions of the tendons, enthesis, tendon sheaths, bursae,
ligaments and fasciae as well as nerve compression syn-
dromes [2]. Corticosteroid injections are frequently
included as treatment option in clinical guidelines in the
field of musculoskeletal disorders. Injectable corticoster-
oids are nowadays registered for local treatment of (rheu-
matic) arthritis, synovitis, bursitis, epicondylitis, tendonitis,
neuromas, ganglion cysts, entrapment syndromes, fasciitis
and back pain [3,4]. In 2006 Dutch pharmacists delivered
208,380 prescriptions of injectable triamcinalone, repre-
senting €2,867,000 of the €86,250,000 total prescribed
medication for the musculoskeletal system (3.3%) [5] it is
however not known how many of the injectable corticos-
teroids are given intra- or extra-articular. In a retrospec-
tive cohort study (on the five-year prognosis of
trochanteric syndrome) 37% of the 164 cases were injected
with corticosteroids [6]. A systematic therapeutic overview
showed that 14-38% of patients with a tennis elbow in
general practice were treated with corticosteroid injections
[7]. In another study in general practice patients with ten-
dosynovitis or nerve entrapment were injected with corti-
costeroid injection in 11% and 13% respectively [8].
Nevertheless there is only limited evidence to support the
superiority of extra-articular glucocorticoid injections
based on randomized trials [9]. Recently in RCT is
reported efficacy of corticosteroid injections for trigger
finger [10]. In addition, safety aspects of corticosteroid
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injections have so far not been adequately investigated by
systematic reviews, except for complications associated
with the use of corticosteroids in the treatment of athletic
injuries [11]. Balanced decisions about healthcare interven-
tions require evidence on harms as well as benefits [12].
Therefore, the aim of the present study was to estimate
the occurrence of and describe the type of adverse effects
due to extra-articular corticosteroid injections.
Methods
Search
The aim was to identify relevant articles describing
adverse events of extra-articular corticosteroid injec-
tions. With our medical librarian (AV) we performed an
extensive literature search in Pub Med and Embase cov-
ering the period 1956 until January 2010. The query was
based on the definitions of terms related to adverse out-
comes as stated in the Cochrane Handbook [13]. The
key words and query comprised a combination of
MESH terms and free-text words for injection locations
(all joints, tendon, bursal, and ligamental location), with
MESH terms for glucocorticosteroid products and the
way of administration combined with all MESH terms
and words related to adverse events. The search query is
added as an additional file(see Additional file 1) In addi-
tion, the titles of references in the included articles or
identified relevant reviews were checked for possibly
relevant references.
Health professionals and patients can report suspicions
of adverse drug reactions to the Netherlands Pharmacov-
igilance Centre ‘Lareb’. The ‘Lareb’ collates adverse drug
reaction data in the Netherlands; it performs this task on
behalf of the Medicines Evaluation Board (MEB) [14].
The MEB is responsible for authorising and monitoring
safe and effective medicinal products on the Dutch
market, and shares in the responsibility for authorizing
medicinal products throughout the European Union.
Therefore we also contacted ‘Lareb’ for relevant data of
adverse events reported after extra-articular corticoster-
oid injection.
Inclusion criteria
Two researchers read a share of the abstracts for inclu-
sion in this review. Only studies that reported original
patient material (e.g. case reports, case studies, cohort
studies, clinical trials and case control studies) that
reported on the occurrence of adverse events after inter-
vention with local non-intra-articular corticosteroid
injections were included. Studies concerning epidural
injection and intramusculair injections were excluded.
Because the adverse events of therapy are not always
mentioned in the article abstracts, the full article of all
relevant clinical trials were carefully read to find any
reported adverse events [15].
Data extraction and data syntheses
Relevant study characteristics (including authors, year of
publication, size of study population, type of interven-
tion) were extracted. In addition, the type and number
of adverse events were extracted, as was the follow-up
time (prospective studies) and percentage lost to follow-
up (as qualitative characteristics). Where possible, the
percentage of persons with adverse events was calcu-
lated separately for major adverse events (defined by us
as having a lasting effect, or needing intervention) and
minor adverse events (defined as transient ones not
needing intervention). In the clinical trials, the frequency
percentage of adverse events was calculated only for the
group receiving intervention with corticosteroids.
Further, a summary of the frequency of such adverse
events was based on prospective studies only. Only in
the case of homogenous definitions of adverse effects,
interventions and study populations we did consider
pooling the risk for adverse-effects. The types of major
and minor adverse events were summarized separately.
The data received from ‘Lareb’ were also analysed
separately. These data include the indication for the cor-
ticosteroid injections, gender of the patient, and route of
administration. We only report here on adverse events
of injections that we know for certain were applied
extra-articularly.
In this review we used the terminology for adverse
drug reactions noted in the Cochrane Handbook [13].
We used the term ‘adverse event’ for an unfavourable
outcome that occurs during or after the use of a drug or
other intervention but is not necessarily caused by it.
‘Adverse effect’ is used for an adverse event for which
the causal relation between the intervention and the
event is at least a reasonable possibility. Adverse drug
reaction’ was used for an adverse effect specific to a
drug. ‘Side effect’ was defined by any unintended effect,
adverse or beneficial, of a drug that occurs at doses nor-
mally used for treatment, and ‘complications’ as an
adverse events or effects following surgical and other
invasive interventions. In the data-extraction, however,
we report the terminology used by the authors.
Results
Output
The search (1956 to January 2010) yielded 1,313 articles.
After reading the abstracts, there were 290 possibly rele-
vant articles on adverse effects after extra-articular injec-
tion. After studying the full-text articles and references
of the included articles and relevant reviews, there were
87 relevant articles, i.e. 44 case reports, 37 prospective
studies and 6 retrospective studies reporting on the
adverse events of extra-articular local corticosteroid
injections.
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‘Lareb’ provided a list of reported adverse events after
triamcinolone injections.
Types of adverse events
Case studies
Only two articles mentioned an adverse event after a
corticosteroid injection in the bursa round the hip. One
of these studies reported a complication after a ten-fold
higher dose was accidentally given [16], and the other
reported a case of a necrotizing fasciitis after a corticos-
teroid injection in the trochanteric bursa - which proved
to be a lethal complication [17]. Necrotizing fasciitis
after corticosteroid injection for trigger finger was pre-
sented as another severe complication [18]. Six studies
described hypopigmentation of the skin [19-24], and
two studies described atrophy of the skin [21,23]. Atro-
phy of the plantar fat pad was reported after injecting
an interdigital neuroma, and another group reported
perilymphatic atrophy [25,26]. Atrophy of the skin and
subcutaneous fat with hyperpigmentation was described
in one patient after intralesional injection of a neuroma
at the feet [27]. A skin defect was observed after two
injections of triamcinolone injected into a hypertrophic
scar [28]. Osteomyelitis of the humerus was reported
after three injections with hydrocortisone for a tennis
elbow [29]. Osteomyelitis of the calcaneus was reported
after an injection for plantar fasciitis [30]. Localized
abscess containing Staphylococcus aureus was described
after injection of corticosteroid for the treatment of
chronic tendinitis of the Achilles tendon [31]. Another
article mentioned a sterile abscess after injecting a
patient with a plantar fasciitis [32]. Protothecosis (a rare
infection caused by an achlorophyllic algae) was seen in
two patients after intralesional injections with corticos-
teroids [33]. Atypical mycobacterium soft tissue infec-
tion was reported after corticosteroid injection for de
Quervain’s disease [34]. An allergic reaction was
reported after giving an injection to a patient who had
tendonitis [35]. A tendon rupture of the hand was
described after an injection into the carpal tunnel, and a
tendon rupture after an injection for tennis elbow
[36,37]. A delayed flexor superficiales and profundus
rupture occurred after a steroid injection for trigger fin-
ger [38]. Seven weight lifters presented at the hospital
with ruptured patellar tendon, they all had a history of
multiple local steroid injections [39]. A rupture of the
Achilles tendon associated with corticosteroid injections
was reported in three studies [40-42]. Another case
report described an avulsion of the calcaneal tendon
after steroid injections administered because of an acute
flare-up of rheumatoid arthritis [43]. One study
described thirteen patients who developed 15 ruptured
tendons subsequent to injection of a depository steroid
in or around the tendons injected [44]. One study
reported ischemia of the hand after carpal tunnel injec-
tion and one study after a corticosteroid injection for de
Quervain tenosynovitis [45,46]. Nerve injury after ster-
oid injection for carpal tunnel syndrome is described in
3 studies [47-49]. Soft tissue calcifications were reported
as a complication due to adjusted materials in the
solvent or due to an accumulation of insoluble steroid
[50-52].
Prospective studies
Of the 37 prospective studies, 11 reported no adverse
effects. Hypopigmentation was reported in three studies
[53-55]. Atrophy was described in four studies
[54,56-58]. Increased or persistent pain after injection or
pain at the site of injection was described in 19 studies.
Adverse events not mentioned in the case reports were
flushes and disturbance in menstrual pattern [59]. Cellu-
litis, ecchymosis and subcutaneous nodule were three
other symptoms not mentioned earlier in the case
reports [55,60]. Table 1 presents information on the
minor and major adverse events in the prospective
studies.
Retrospective studies
In one retrospective study septic bursitis was described
after corticosteroid injection in traumatic olecranon bur-
sitis [61]. Tachon’s syndrome (subacute back pain and/
or thoracic pain following local injections of corticoster-
oids) was reported in one study [62]. Table 2 presents
information on the adverse events in the retrospective
studies.
Lareb Institute
The following adverse events were registered by the
‘Lareb’ institute following extra-articular indications:
after corticosteroid injection for bursitis trochanterica
flushing was reported, after injection for tennis elbow,
rash, menstrual disorder, and skin depigmentation and
in one patient dyspnoea and eyelid ptosis were reported.
In one patient hallucination, increased intracranial and
intraocular pressure, and paresis occurred after corticos-
teroid injection for a calcaneal spur. In another patient,
after corticosteroid injection for carpal tunnel syndrome
hirsutism, nail changes and vaginal hemorrhage were
reported. After injection for trigger finger an allergic
skin reaction was observed. Reported adverse events
after corticosteroid injections for tendonitis were: ana-
phylactic reaction in one patient, erythema and skin
atrophy in another, and rash and tendon disorder in the
third patient.
Frequency of adverse events Due to the heterogeneity
of the study populations, the type of interventions, the
uncertain causality of the reported reaction with the
administered corticosteroid injection and the impossibil-
ity to count risk differences in all the studies, we
refrained from pooling the risk for adverse-effects.
Minor adverse events were:
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Table 1 Summary of the included prospective studies
Author, Year of
publication
Type of
study,
number
of cases
Indication Corticosteroid injection
agent (no. of injected
cases, sides)
Methods of reporting
adverse events
Complications reported
Major/minor Period of
time
Follow-up
(%)
Rompe 2009 [69] RCT
(229)
GTPS Prednisolon 25 mg/
meaverin 0.5% (75)
In method section: adverse
effects were recorded by the
physician Results:
summarised in a table
Minor: increased or
radiating pain: 44%, skin
irritation 3%, swelling 9%
92% after
15 months
Gunter 2004 [70] RCT (18) Iliotibial
band friction
syndrome
Methylprednisolone acetate
40 mg/lignocaine 1% (9)
In method section: side
effects/adverse reactions: are
reported in both
intervention groups as a
separate issue Results:
mentioned as a separate
issue
No side-effects after 7 and
14 days
100% at
2 weeks
Chao 2009 [71] RCT (97) Trigger
thumb
Triamcenolon 10 mg (42) In method section: no
information Results:
mentioned in a sentence
Minor: 2.2% had pain after
1 month
100% after
12 months
Peters 2008 [72] RCT (50) Trigger
finger
Triamcinolone acetonide: 10,
1 or 2 injections (41)
In method section: adverse
event as secondary outcome
Results: mentioned as a
separate issue
Minor: hot flushes 22%,
steroid-flare 14.6%
82% after
12 months
follow-up
Jianmongkol 2007
[73]
RCT
(101)
Trigger
finger, 2
types of
injection
therapy
were
compared
(48/53)
Triamcinolone 10 mg/
lidocaine (101)
In method section: no
information Results: reported
in one sentence
No complications Follow-up 6
weeks (%
lost to
follow-up
not
mentioned)
Goldfarb 2007 [74] RCT
(154)
Trigger
finger or De
Quervain’s
tenosynovitis
Methylprednisolone acetate
40 mg/lidocaine 1%/
bupivacaine 0.5% (154)
In method section:
incidence of post injection
pain flare was the aim of
the study, no other
complications are monitored
Results: flare reaction
mentioned as a separate
issue
Minor: in 33% increase in
pain score of 2 points or
more (VAS scale 0-10).
81% follow-
up after 1
and 6
weeks
Baumgarten 2007
[75]
RCT (59) Trigger
finger in
diabetics
versus non
diabetics
Betamethasone 6 mg/
lidocaine 1% (44)
In method section: in follow-
up section: complications
related to treatment were
reported Results:
complications reported as a
separate issue
No adverse events at 6
weeks, 3 months and 1
year
98% follow-
up at 12
month
(range 13-
41 months)
Kazuki 2006 [76] Pros
(100)
Trigger
finger
Betamethasone 2.5 mg/
lidocaine 1% (129 fingers)
In method section: not
mentioned. Results: one
sentence: no complications
of steroid injections were
observed
No complications after 6
months
100%
follow-up
after
6 months
(range 1-42)
Gurcay 2009 [77] RCT (36) Carpal
tunnel
syndrome
Betamethasone 6 mg (18) In method section: not
mentioned Results: no
complications or side effects
to treatment were observed
No side effects 100%
follow-up
after
3 months
Nalamachu 2006
[78]
RCT (40) Carpal
tunnel
syndrome
Methylprednisolone 40 mg/
lidocaine 1% (20)
In method section: adverse
events were classified
according to MedDRA and
the incidence of treatment
emergent events was
summarized Results: adverse
events were described
Minor: numbness (5%),
local pain (5%), tingling in
hands at 4 weeks (5%)
85% follow-
up after
4 weeks
Dammers 2005
[79]
RCT
(132)
Carpal
tunnel
syndrome
Methylprednisolone 20 mg
(45), 40 mg (43), 60 mg (44)
with lidocaine 10 mg
In method section: not
mentioned Results: no side
effects were recorded
No side-effects after 1 and
12 months
97% follow-
up after
12 months
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Table 1 Summary of the included prospective studies (Continued)
Hui 2005 [60] RCT (50) Carpal
tunnel
syndrome
Methylprednisolon 15 mg
(25)
In method section: surgical
complications are assessed
after one week, no other
adverse events mentioned.
Results: one patient with
cellulitis is reported and four
patients with pain at the
injection side
Minor: pain at injection
side 16% Major: cellulitis
4%
100% at
6 and
20 weeks
Wong 2005 [80] RCT (40) Carpal
tunnel
syndrome
Methylprednisolone 15 mg
single dose (20) or double
dose (20)
In method section: any side
effects were recorded at 8,
24 and 40 weeks Results:
reported as a sentence at
the end of the result section
Minor: local pain (30% in
20 mg group and 10% in
20 mg group)
100%
follow-up at
8 weeks
Agarwal 2005 [81] Pros (48) Carpal
tunnel
syndrome
Methylprednisolone acetate
40 mg/xylocaine 2%
(67 hands)
In method section: not
mentioned Results: at the
end of the result section
adverse effects were
mentioned
Minor: mild discoloration of
the skin over the injection
site (6%)
100%
follow-up
after 3
months,
78% after
12 months
Ly-Pen 2005 [82] RCT
(163)
Carpal
tunnel
syndrome
Paramethasone acetonide
20 mg (82, 69 wrists
required second injection)
In method section: not
mentioned Results: safety
and tolerability was a
separate chapter
No relevant side-effects 79.5%
follow-up at
12 months
Sevim 2004 [83] RCT
(120)
Carpal
tunnel
syndrome
Betamethasone 6 mg. (60) In method section: not
mentioned Results:
complications and side
effects are described
Minor: moderate pain
lasting less than 24 hours
after injection (3.4%),
haematoma (1.7%)
90% follow-
up at
11 months
follow-up
(range 9 to
14 months)
Armstrong 2004
[84]
RCT (81) Carpal
tunnel
syndrome
Betamethasone 6 mg/
lidocaine 1% (43 with a
total of 364 injections)
In method section: side
effects and complications
are recorded Results: adverse
effects described
Minor: severe pain after
injection (5%), acute
transient sympathetic
reaction after injection (2%)
89% follow-
up after 18
months
Wong 2001 [85] RCT (62) Carpal
tunnel
syndrome
Methylprednisolone 15 mg
(30)
In method section: any side
effects were recorded by
telephone interview Results:
summarized in a table
Minor: injection pain (6.7%) 100% after
12 weeks
Kalaci 2009 [64] RCT
(100)
Plantar
fasciitis
Triamcinolone 20 mg (50) In method section: not
mentioned Results:
description of the side
effects not found
No side effects or
complications All of the
patients found the
injection painful
100% after
6 months
Porter 2005 [86] RCT
(132)
Plantar
fasciopathy
Betamethason 5.7 mg/
lignocaine 1% (64)
In method section: patients
were asked to report any
possible side effects at 3
and 12 months Results: no
infections or rupture are
found, description of the
side effects
Minor: post-injection pain
(12.5%) that required
analgesia and/or ice
application
95% follow-
up at 12
months
Genc 2005 [87] Pros (30) Plantar
fasciitis
Methylprednisolone 20 mg/
prolocaine 2% (47 heels)
In method section:
ultrasonografy measurement
of the facia at 1 and 6
months Results: reported as
one sentence
No rupture observed 100%
follow-up at
6 months
Lindenhovius 2008
[88]
RCT (64) Lateral
elbow pain
Dexamethasone 4 mg/
lidocaine 1% (31)
In method section: not
mentioned Results: adverse
events are described
Minor: discoloration of skin
3.2% increased elbow pain
3.2%
77% after
1 and 6
months
Tonks 2007 [53] RCT (48) Epicondylitis
lateralis
Triamcinolone acetonide
10 mg/lignocaine 2% (24)
In method section:
complications of treatment
were one of the outcome
measurements Result
section: complications are
described
Major: skin depigmentation
and atrophy in 4% after 7
weeks
77% follow-
up at
7 weeks
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Table 1 Summary of the included prospective studies (Continued)
Bisset 2006 [54] RCT
(198)
Tennis
elbow
Triamcinolone 10 mg/
lidocaine 1% (65)
In method section: not
mentioned Results: side
effects were mentioned in a
separate section
Minor: pain (18.5%). Major:
loss of skin pigment (3%),
atrophy of subcutaneous
tissue (1.5%)
100%
follow-up in
injection
group at
12 months
Wang 2003 [89] Pros (94) Hand and
elbow
injections
Betamethasone/lidocaine
1%
In method section:
registration of pain levels
after injection of
corticosteroid to hand and
elbow was the aim of the
study, no other side effects
were recorded Results: post
injection pain is shown in
table and list
Minor: 50% increased post-
injection pain during 1.2
days
71% follow-
up at 5
days
Smidt 2002 [90] RCT
(185)
Epicondylitis
lateralis
Triamcinolone acetonide 10
mg/lidocaine (62)
In method section: details of
any adverse effects were
reported on standardised
forms Results: adverse
effects summarized in a
table
Minor: facial flush (3%), skin
irritation (5%), red swollen
elbow (3%), change of skin
colour (11%), other not
specified side-effects (13%)
96% follow-
up at 52
weeks
Jensen 2001 [91] RCT (30) Tennis
elbow
Methylprednisolone 20 mg/
lidocaine 1% (16)
In method section: daily
pain registration for six
weeks Results: described in
result section
Minor: pain increase after
injection (81%)
100%
follow-up
6 weeks
Hay 1999 [57] RCT
(164)
Tennis
elbow
Methylprednisolone 20 mg/
lignocaine (51)
In method section:
complications of treatment
is one of the secondary
outcome Results: described
in a separate section side
effects
Major: local skin atrophy in
the overall group (3 of
111), one with steroids
(1.9%)
100%
follow-up at
12 months
Stahl 1997 [92] RCT (58) Medial
epicondylitis
Methylprednisolone 40 mg/
lidocaine (30)
In method section:
interviews and physical
examination for possible
local complications Results:
complications are reported
in a separate part
Major: non reported Minor:
facial flushing in one
female patient
100%
follow-up
12 months
Verhaar 1995 [93] RCT
(106)
Tennis
elbow
Triamcinolone 1% (53) In method section: side
effects not specified Results:
no infection or skin
hypopigmentation
No side effects in the
injection group
100% follow
up after 12
months
Price 1991 [58] RCT
(145)
Tennis
elbow
Triamcinolone 10 mg/
lignocaine 1% or
Hydrocortisone 25 mg/
lignocaine 1% compared
with lignocaine 1% or with
Triamcinolone 20 mg.
Second study Triamcinolone
10 mg versus 20 mg
In method section: severe
post-injection pain and skin
atrophy were noted Results:
table with the adverse
effects
Minor: post-injection pain
(11%-58%). Major: skin
atrophy (17%-40%)
Follow-up
at 24 weeks
(% lost to
follow-up
not clear)
Jirarattanaphochai
2004 [55]
RCT
(160)
De
Quervain’s
tenosynovitis
Triamcinolone acetonide
10 mg (100)
In method section: the
adverse events reported at 3
weeks, 6 and 12 months are
secondary outcome
measurements Results:
adverse effects are
mentioned in a table
Minor: post-injection pain
(13%), subcutaneous
nodule (2.5%), ecchymosis
(1.3%). Major: skin
hypopigmentation (1.3%)
100%
follow-up,
3% lost
between
6 and
12 months
Avci 2002 [94] CT (19) Pregnant or
lactating
women with
De
Quervain’s
tenosynovitis
Methylprednisolone 10 mg
(10)
In method section: not
mentioned Result section:
not specified
No side effects or local
complications of
corticosteroid injection
were noted
100% follow
(range 9-
17 months)
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- pain after injection with a frequency ranging from
3.4-81%
- numbness and tingling in hands was reported in one
study on CTS patients in 5% of the cases
- mild discoloration of the skin over the site of injec-
tion in three studies in 3.2%, 6% and 11.2%, respectively
- disturbance in menstruation in one study in 50.6% of
the patients, and flushes in 3 studies with a frequency of
3.2%, 22% and 28.6%, respectively
-transient sympathetic reaction in one study with a
frequency of 2%
- ecchymosis in one study with a frequency of 1.3%
Major adverse events in the prospective studies were:
- skin depigmentation reported in 3 studies with a fre-
quency ranging from 1.3-4%
- atrophy was mentioned in 5 studies with a frequency
ranging from 1.5-40%
- cellulitis was reported in one study in 4% of the
patients
Discussion
In this review, reported dermal adverse events of local
corticosteroid injections were irritation, change of skin
colour, skin and perilymphatic atrophy, soft tissue calci-
fication, skin defect, hypopigmentation, sterile abscess,
ecchymosis, and allergic rash. The infectious adverse
Table 1 Summary of the included prospective studies (Continued)
Anderson 1991[95] Pros (56) De Quervain
tenosynovitis
Methylprednisolone acetate
40 mg
In method section: adverse
reaction were recorded,
particularly signs of atrophy
Result: adverse reactions are
summarised in a table
Minor; pain 18%, pain,
swelling, heat 5%
ecchymosis 9% temporary
radial nerve paresthesia 2%
vasovagal reaction 2%
Major: subcutaneous fat
atrophy 16%
95% follow-
up at
4.2 years
Crawford 1999
[96]
RCT
(106)
Heel pain Methylprednisolone 25 mg
(53)
In methods and results
sections: not mentioned
No side-effects reported 52% follow-
up after
6 months
Capasso 1997 [97] RCT
(116)
Patellar
tendopathy
Methylprednisolone 40 mg/
lignocaine (39)
In method section: not
mentioned Results:
acceptability of treatment is
separately discussed in a
chapter
Minor: burning sensation
(10.3%) injection pain
(5.1%)
82% follow-
up after
12 months
Mens 1998 [59] Pros
(77 ♀)
Musculo-
skeletal
disease
Triamcinolone acetate intra-
articular (46) and extra-
articular (24)
Method section: patients
were asked to report
appearance of flushing and
any abnormality of the
menstrual pattern Results:
shown in a table
Disturbance in
menstruation at 6 weeks
(50.6%), flushes (28.6%)
100%
follow-up
after
6 weeks
RCT: randomized controlled trial, CT: controlled trial, Pros: prospective clinical study
Table 2 Summary of the included retrospective studies
Author, Year
of publication
Type of study Indication Corticosteroid used Complication (number of cases)
Berthelot 2004
[62]
Questionnaire sent to
500 rheumatologist
Different rheumatologic
diseases
Cortivazol Hydrocortisone
Betamethasone
Paramethasone
Tachon’s syndrome (n = 318) *
Cill 2004 [98] 48 cases Achilles tendinopathy Triamcinolone 10 mg and 20
mg with bupivacaine 0.25%
No major complications, 1 patient (2%) reported
purple skin dicoloration
Bjorkman 2004
[99]
27 cases Rupture of the tendon
extensor pollicis longus
2 oral corticosteroids and 2
local corticosteroid injections
Rupture of the tendon extensor pollicis longus
n = 4 associated with use of corticosteroids
Acevedo 1998
[100]
765 cases Plantar fasciitis Triamcinolone 40 mg (122) Plantar fascia rupture (n = 44) **
Astrom 1998
[101]
298 cases Achilles tendinopathy Unknown Preoperative steroid injection was predictive of
a partial rupture***
Weinstein 1984
[61]
Follow-up of 47 cases Traumatic olecranon
bursitis
25 patients received
Triamcinolone 20 mg after
aspiration
septic bursitis (9%) skin atrophy (25%) chronic
pain (28%)
* 1 event per 8,000 injections
** 44 of the 51 plantar fascia ruptures were associated with corticosteroids injection
***Odds ratio 2.0 (CI 1.3-9.8)
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events were cellulites, localized abscess, septic bursitis,
atypical mycobacterium infection, necrotizing fasciitis,
and protothecosis. Local adverse events included local
pain, tingling or numbness in hands, local neural
damage and tendon rupture. Systemic adverse events
included allergic reactions, facial flush and disturbance
in menstrual pattern.
Edwards and Aronson defined an adverse drug reac-
tion as “an appreciably harmful or unpleasant reaction,
resulting from an intervention related to the use of a
medicinal product, which predicts hazard from future
administration and warrants prevention or specific treat-
ment, or alteration of the dosage regimen, or withdrawal
of the product“ [63]. According to the WHO they clas-
sify adverse drug reactions into six types: dose-related,
non dose-related, dose-related and time-related, time-
related, withdrawal, and failure of therapy. In the pre-
sent review we were unable to categorize the adverse
drug reaction in this way. We neither were able to judge
the causal relation between the reported reactions and
the administered drug, so we are about speaking of
adverse events rather than adverse drug reactions. In
addition, in table 1 we reported the terminology as
described in the individual articles, because it was not
always clear which classification system they used.
Although the adverse events reported in our review are
‘miscellaneous’ ones, we think that these types of
adverse events (occurring after a regular dose of extra-
articular corticosteroid injections) can be divided in sys-
temic adverse events and local adverse events. The sys-
temic adverse events can be divided into allergic
reactions (IgE mediated) or other hypersensitivity reac-
tions, disturbance in menstruation, flushes and Tachon’s
syndrome and systemic infection. The local effects con-
sisted of local pain, degeneration, atrophy and change in
skin colour, local infection, impact on collagen metabo-
lism expressed as tendon ruptures, and perilymphatic
atrophy. Depending on the place where the injection is
administered, adverse events can manifest, for example,
injections for plantar fasciitis are almost painful [64].
Injections in general can cause substantial adverse
effects. For example, Nicolau’s syndrome (livedoid der-
matitis secondary to acute arterial thrombosis after
injection in a blood vessel) has been described after an
intra-articular corticosteroid injection [65]. Such an
adverse event would be extremely rare after injection in
a bursa or other superficial structures. The venous
counterpart, known as Tachon’s syndrome (subacute
back pain and/or thoracic pain following local injections
of corticosteroids), was reported in a retrospective study
[62]. In general it obvious that adverse events associated
with corticosteroid injection can be minimised by ensur-
ing appropriate injecting procedures are followed by a
well-trained practitioner. Neural damage after injecting
CTS might be avoided by proper injection technique
[66]. In this review we divided the adverse events into
minor ones (the harm was temporary) and major ones
(the adverse event needed intervention or was not tran-
sient). This clinical categorization, although not
approved by the WHO or FDA, might help to make a
more balanced decision regarding the (possible) harm of
an injection with corticosteroids for extra articular use.
In addition, it can be easily explained to patients.
The Cochrane Collaboration provides guidance from
the Adverse Effects Subgroup of the Non-randomized
Studies Methods Group [13]. An appendix provides
information on adverse effects, advice and tips about the
search strategy and the type of studies to be included.
However, we failed to find all the relevant articles with
the search strategy advised by the Cochrane Collabora-
tion and had to expand the search strategy. In our
review, we did not use an overall quality assessment.
We did describe however, the methods of reporting
adverse events for each prospective study, the duration
of follow-up, and the percentage lost to follow-up. The
drawback of our study is that we could not assess the
risk of bias. Clinical trials, cohort studies and case stu-
dies have their own risk of bias [13]. The limitations of
the case reports are that there is uncertainty as to the
adverse event was caused by the corticosteroid injection.
Similarly, the lack of a control group in the prospective
study on reporting specified menstruation disorders
afterwards cannot prove the causal relationship [59]. If
we assume that the internal validity for assessing adverse
events in RCT at least should be based on the percen-
tage available for follow-up (i.e. 80% or more) and sys-
tematic registration of adverse events and a comparison
against a control group, then using these criteria less
than half of the prospective studies in this review were
of inferior quality.
Some RCTs assess smaller numbers of patients thus
decreasing the chance of detecting a rare adverse event.
Moreover, a part of the RCTs cover a relatively short
study period thus precluding the identification of
delayed or prolonged, and generally have highly specific
inclusion/exclusion criteria that may imply that the
results cannot be generalized to other populations.
Therefore, the assessment of safety needs to cover not
only RCTs but also explore other sources such as, for
example, post-marketing surveillance studies, sponta-
neous reporting schemes, and epidemiological studies.
Systematic reviews on the safety of therapeutic interven-
tions should preferably combine data from various types
of studies [67].
In prospective studies, adverse effects attributed to the
specific intervention should preferably be estimated by
risk ratios, where the risk for adverse effects in the
intervention group is compared with that for those who
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did not receive the intervention. In the present review,
because all subjects included in the prospective studies
received the intervention, only the percentage of adverse
effects could be estimated. For this reason, in the RCTs
we estimated the percentage of adverse effects for the
intervention group only and did not compare these data
with the control group. However, because the types of
adverse event reported in these RCTs were highly inter-
vention-specific we do not expect an overestimation of
the adverse effects. In fact, based on the inadequate/lack
of systematic registration in the included studies, we
suspect there may even be an underestimation of the
adverse-effects. Therefore we advocate that future RCTs
and prospective studies should report on adverse events
following the recommendations in the CONSORT
guidelines [68].
Conclusion
In this literature review it was difficult to accurately
quantify the incidence of adverse effects after extra-
articular corticosteroid injection. Although one fatal
adverse event after an extra-articular corticosteroid
injection was reported, extra-articular corticosteroid
injections are regularly administered worldwide. In the
present review the incidence of major adverse events
(according to our definition) was up to 5.8%, ranging
from depigmentation and atrophy of the skin to celluli-
tis; generally speaking these adverse effects could per-
haps be classified as ‘relatively mild’. Based on these
data the administration of extra-articular corticosteroid
injections seems to be a ‘relatively safe’ intervention.
Additional material
Additional file 1: Search strategy in Pubmed and Embase. Word
DOC displaying search strategy in Pubmed and Embase.
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